Faculty Opinions recommendation of Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists.

2021 ◽  
Author(s):  
Emmanuel Darcq
Keyword(s):  
G Protein ◽  
Side Effect ◽  
Protein Activation ◽  
Intrinsic Efficacy ◽  
Opioid Agonists ◽  
G Protein Activation

scholarly journals Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists

2020 ◽  
Vol 13 (625) ◽  
pp. eaaz3140 ◽  
Author(s):  
Alexander Gillis ◽  
Arisbel B. Gondin ◽  
Andrea Kliewer ◽  
Julie Sanchez ◽  
Herman D. Lim ◽  
...  
Keyword(s):  
G Protein ◽  
Side Effect ◽  
Opioid Analgesics ◽  
Receptor Activation ◽  
Alternative Mechanism ◽  
Protein Activation ◽  
Biased Agonism ◽  
Opioid Ligands ◽  
Intrinsic Efficacy ◽  
Respiratory Depressant

Biased agonism at G protein–coupled receptors describes the phenomenon whereby some drugs can activate some downstream signaling activities to the relative exclusion of others. Descriptions of biased agonism focusing on the differential engagement of G proteins versus β-arrestins are commonly limited by the small response windows obtained in pathways that are not amplified or are less effectively coupled to receptor engagement, such as β-arrestin recruitment. At the μ-opioid receptor (MOR), G protein–biased ligands have been proposed to induce less constipation and respiratory depressant side effects than opioids commonly used to treat pain. However, it is unclear whether these improved safety profiles are due to a reduction in β-arrestin–mediated signaling or, alternatively, to their low intrinsic efficacy in all signaling pathways. Here, we systematically evaluated the most recent and promising MOR-biased ligands and assessed their pharmacological profile against existing opioid analgesics in assays not confounded by limited signal windows. We found that oliceridine, PZM21, and SR-17018 had low intrinsic efficacy. We also demonstrated a strong correlation between measures of efficacy for receptor activation, G protein coupling, and β-arrestin recruitment for all tested ligands. By measuring the antinociceptive and respiratory depressant effects of these ligands, we showed that the low intrinsic efficacy of opioid ligands can explain an improved side effect profile. Our results suggest a possible alternative mechanism underlying the improved therapeutic windows described for new opioid ligands, which should be taken into account for future descriptions of ligand action at this important therapeutic target.

scholarly journals Re-evaluating how low intrinsic efficacy and apparent bias for G protein activation relates to the improved side effect profiles of new opioid agonists

2020 ◽  
Author(s):  
Edward L. Stahl ◽  
Laura M. Bohn
Keyword(s):  
G Protein ◽  
Therapeutic Window ◽  
G Protein Signaling ◽  
Protein Signaling ◽  
Protein Activation ◽  
Biased Agonism ◽  
Intrinsic Efficacy ◽  
Cellular Environment ◽  
G Protein Activation ◽  
G Protein Coupled

AbstractIn a recent report by Gillis et al., 2020 (1), it was suggested that low intrinsic agonism, and not biased agonism, leads to an improvement in the separation of potency in opioid-induced respiratory suppression versus antinociception. Although the compounds that were tested have been shown to display G protein signaling bias in prior publications, the authors conclude that since they cannot detect biased agonism in their cellular signaling studies the compounds are therefore not biased agonists. Rather, they conclude that it is low intrinsic efficacy that leads to the therapeutic window improvement. Intrinsic efficacy is the extent to which an agonist can stimulate a G protein-coupled receptor (GPCR) response in a system. The designation of full agonist is made to compounds that produce the highest observable activation in a system (maximum intrinsic efficacy); agonists producing some fraction of that response are considered partial agonists. The maximum response window is determined by the cellular environment, receptor and effector expression levels, and the amplification readout of the system. Biased agonism takes into consideration not only intrinsic efficacy, but also potency (concentration required to reach half maximal efficacy) of an agonist in an assay. Herein, the data published in the aforementioned manuscript was used to rederive the intrinsic efficacy and bias factors as ΔΔlog(τ/KA) and ΔΔlog(Emax/EC50). Based on this reanalysis, the data does not support the conclusion that biased agonism, favoring G protein signaling, was not present. Further, these observations agree with prior studies wherein oliceridine, PZM21 and SR-17018 were first described as biased agonists with improvement in antinociception over respiratory suppression in mice. Therefore, introducing G protein signaling bias may be a means to improve opioid analgesia while avoiding certain undesirable side effects.

scholarly journals Opioid Agonists Have Different Efficacy Profiles for G Protein Activation, Rapid Desensitization, and Endocytosis of Mu-opioid Receptors

2003 ◽  
Vol 278 (21) ◽  
pp. 18776-18784 ◽  
Author(s):  
Stephanie L. Borgland ◽  
Mark Connor ◽  
Peregrine B. Osborne ◽  
John B. Furness ◽  
MacDonald J. Christie
Keyword(s):  
G Protein ◽  
Opioid Receptors ◽  
Mu Opioid Receptors ◽  
Mu Opioid ◽  
Protein Activation ◽  
Opioid Agonists ◽  
G Protein Activation

scholarly journals β2-adrenoceptor ligand efficacy is tuned by a two-stage interaction with the Gαs C terminus

2021 ◽  
Vol 118 (11) ◽  
pp. e2017201118
Author(s):  
Keehun Kim ◽  
Shayla Paulekas ◽  
Fredrik Sadler ◽  
Tejas M. Gupte ◽  
Michael Ritt ◽  
...  
Keyword(s):  
G Protein ◽  
Dynamic Range ◽  
Receptor Activation ◽  
Activation Mechanism ◽  
Two Stage ◽  
Protein Activation ◽  
Intrinsic Efficacy ◽  
C Terminus ◽  
G Protein Activation ◽  
Structural Determinant

Classical pharmacological models have incorporated an “intrinsic efficacy” parameter to capture system-independent effects of G protein–coupled receptor (GPCR) ligands. However, the nonlinear serial amplification of downstream signaling limits quantitation of ligand intrinsic efficacy. A recent biophysical study has characterized a ligand “molecular efficacy” that quantifies the influence of ligand-dependent receptor conformation on G protein activation. Nonetheless, the structural translation of ligand molecular efficacy into G protein activation remains unclear and forms the focus of this study. We first establish a robust, accessible, and sensitive assay to probe GPCR interaction with G protein and the Gα C terminus (G-peptide), an established structural determinant of G protein selectivity. We circumvent the need for extensive purification protocols by the single-step incorporation of receptor and G protein elements into giant plasma membrane vesicles (GPMVs). We use previously established SPASM FRET sensors to control the stoichiometry and effective concentration of receptor–G protein interactions. We demonstrate that GPMV-incorporated sensors (v-SPASM sensors) provide enhanced dynamic range, expression-insensitive readout, and a reagent level assay that yields single point measurements of ligand molecular efficacy. Leveraging this technology, we establish the receptor–G-peptide interaction as a sufficient structural determinant of this receptor-level parameter. Combining v-SPASM measurements with molecular dynamics (MD) simulations, we elucidate a two-stage receptor activation mechanism, wherein receptor–G-peptide interactions in an intermediate orientation alter the receptor conformational landscape to facilitate engagement of a fully coupled orientation that tunes G protein activation.

Opioid-Activated Postsynaptic, Inward Rectifying Potassium Currents in Whole Cell Recordings in Substantia Gelatinosa Neurons

1998 ◽  
Vol 80 (6) ◽  
pp. 2954-2962 ◽  
Author(s):  
S. P. Schneider ◽  
W. A. Eckert ◽  
A. R. Light
Keyword(s):  
Membrane Potential ◽  
G Protein ◽  
Potassium Currents ◽  
Substantia Gelatinosa ◽  
Opioid Agonist ◽  
Membrane Hyperpolarization ◽  
Whole Cell ◽  
Protein Activation ◽  
G Protein Activation ◽  
Whole Cell Recordings

Schneider, S. P., W. A. Eckert III, and A. R. Light. Opioid-activated postsynaptic, inward rectifying potassium currents in whole cell recordings in substantia gelatinosa neurons. J. Neurophysiol. 80: 2954–2962, 1998. Using tight-seal, whole cell recordings from isolated transverse slices of hamster and rat spinal cord, we investigated the effects of the μ-opioid agonist (d-Ala2, N-Me-Phe4,Gly5-ol)-enkephalin (DAMGO) on the membrane potential and conductance of substantia gelatinosa (SG) neurons. We observed that bath application of 1–5 μM DAMGO caused a robust and repeatable hyperpolarization in membrane potential ( V m) and decrease in neuronal input resistance ( R N) in 60% (27/45) of hamster neurons and 39% (9/23) of rat neurons, but significantly only when ATP (2 mM) and guanosine 5′-triphosphate (GTP; 100 μM) were included in the patch pipette internal solution. An ED50 of 50 nM was observed for the hyperpolarization in rat SG neurons. Because G-protein mediation of opioid effects has been shown in other systems, we tested if the nucleotide requirement for opioid hyperpolarization in SG neurons was due to G-protein activation. GTP was replaced with the nonhydrolyzable GTP analogue guanosine-5′- O-(3-thiotriphosphate) (GTP-γ-S; 100 μM), which enabled DAMGO to activate a nonreversible membrane hyperpolarization. Further, intracellular application of guanosine-5′- O-(2-thiodiphosphate) (GDP-β-S; 500 μM), which blocks G-protein activation, abolished the effects of DAMGO. We conclude that spinal SG neurons are particularly susceptible to dialysis of GTP by whole cell recording techniques. Moreover, the depletion of GTP leads to the inactivation of G-proteins that mediate μ-opioid activation of an inward-rectifying, potassium conductance in these neurons. These results explain the discrepancy between the opioid-activated hyperpolarization in SG neurons observed in previous sharp electrode experiments and the more recent failures to observe these effects with whole cell patch techniques.

Sign in / Sign up

Export Citation Format

Share Document